NEOADJUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MULTICENTER RANDOMIZED PHASE II TRIAL
Phase 2 – studying effectiveness and dosage
Conditions:
Hepatocellular carcinoma
Sponsor: Centre Hospitalier Universitaire De Montpellier
trial.available_in:
БГ
Overview
Trial status: Authorised
Recurrence-free survival: Recurrence is defined as recurrence or death, whichever comes first. Recurrence is defined as emergence of ≥ 1cm nodules enhanced at arterial phase followed by washout at portal or late phase observed on MRI, or any atypical nodule on imaging with histological features of HCC (EASL guidelines). Emergence of extrahepatic metastasis is also considered as a recurrence. Patients will be followed by MRI, 3, 6, 9, 12, 15, 18, 21and 24 months after randomization
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 202 participants
БГ